We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-10.7%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.35B
AUM Growth
-$119M
(-4.8%)
Cap. Flow
-$74.1M
Cap. Flow
% of AUM
-3.15%
Top 10 Holdings %
Top 10 Hldgs %
36.4%
Holding
125
New
15
Increased
30
Reduced
16
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$76.3M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$48.9M |
| 3 |
Editas Medicine
EDIT
|
+$44.9M |
| 4 |
Viatris
VTRS
|
+$37.5M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
+$84.3M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$53.5M |
| 3 |
Charles River Laboratories
CRL
|
+$30.3M |
| 4 |
GHDX
Genomic Health, Inc.
GHDX
|
+$28.5M |
| 5 |
Pacira BioSciences
PCRX
|
+$28.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.81% |
| 2 | Financials | 4.2% |
| 3 | Technology | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Voyager Therapeutics
VYGR
$192M
| $2.05M | 0.09% |
235,294
| – | – |
|
77
Aldeyra Therapeutics
ALDX
$103M
| $1.98M | 0.08% |
471,259
-219,279
| -32% | -$1.05M |
|
|
TRIL
78
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.59M | 0.07% |
172,307
| – | – |
|
|
AGRX
79
DELISTED
Agile Therapeutics
AGRX
| $1.55M | 0.07% |
+125
| New | +$1.61M |
|
80
Trupanion
TRUP
$1.15B
| $1.53M | 0.07% |
155,236
-906,978
| -85% | -$8.12M |
|
81
Alphatec Holdings
ATEC
$1.3B
| $1.2M | 0.05% |
415,228
| – | – |
|
82
CareDx
CDNA
$2B
| $1.14M | 0.05% |
229,000
| – | – |
|
|
AGN
83
DELISTED
Allergan plc
AGN
| $938K | 0.04% |
+3,500
| New | +$1M |
|
|
STRM
84
DELISTED
Streamline Health Solutions
STRM
| $935K | 0.04% |
44,198
| – | – |
|
85
Veracyte
VCYT
$4.64B
| $892K | 0.04% |
165,097
-227,050
| -58% | -$1.34M |
|
|
CDTX
86
DELISTED
Cidara Therapeutics
CDTX
| $873K | 0.04% |
3,439
-2,534
| -42% | -$584K |
|
87
Pfizer
PFE
$143B
| $741K | 0.03% |
+26,350
| New | +$753K |
|
|
ADYX
88
DELISTED
Adynxx Inc
ADYX
| $547K | 0.02% |
11,121
-20,215
| -65% | -$1.62M |
|
|
PTN
89
Palatin Technologies
PTN
$16.2M
| $532K | 0.02% |
789
-811
| -51% | -$528K |
|
|
WMGI
90
DELISTED
Wright Medical Group Inc
WMGI
| $498K | 0.02% |
+30,000
| New | +$556K |
|
|
RNVA
91
DELISTED
Rennova Health, Inc.
RNVA
| $265K | 0.01% |
787
-456
| -37% | -$168K |
|
|
OCRX
92
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $221K | 0.01% |
+75,293
| New | +$215K |
|
93
Apyx Medical
APYX
$179M
| – | – |
-688,229
| Closed | -$1.45M |
|
94
Centene
CNC
$32.9B
| – | – |
-488,000
| Closed | -$16.1M |
|
95
Cencora
COR
$59.5B
| – | – |
-3,000
| Closed | -$311K |
|
|
96
Charles River Laboratories
CRL
$10.5B
| – | – |
-377,188
| Closed | -$30.3M |
|
97
CALL
Gilead Sciences
GILD
$166B
| – | – |
-532,000
| Closed | -$53.8M |
|
98
Pacific Biosciences
PACB
$441M
| – | – |
-1,388,000
| Closed | -$18.2M |
|
|
99
Pacira BioSciences
PCRX
$1.01B
| – | – |
-371,000
| Closed | -$28.5M |
|
|
100
CALL
Teva Pharmaceuticals
TEVA
$37.4B
| – | – |
-550,000
| Closed | -$36.1M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q1 2016 Portfolio in Review
As of Q1 2016, Deerfield Management held 125 positions worth $2.35B, down 4.8% from $2.47B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Deerfield Management withdrew a net $74.1M in Q1 2016, closing 20 positions and reducing 16 holdings. Its most notable exit was DYAX CORPORATION, an estimated $84.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 68% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in AveXis, Inc. Common Stock worth $60.9M.
- Deerfield Management's largest Q1 2016 buy was AveXis, Inc. Common Stock: 2,236,701 shares worth $60.9M.
- Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q1 2016, an estimated $76.3M increase.
- Deerfield Management's biggest Q1 2016 reduction was Adeptus Health Inc, cutting an estimated $18.2M.
- Deerfield Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $84.3M.
- Deerfield Management's ten largest holdings make up 36% of its $2.35B portfolio in Q1 2016.
- Deerfield Management opened 15 new positions and closed 20 in Q1 2016.
- Deerfield Management's portfolio value fell 4.8% quarter-over-quarter to $2.35B.
Based on Deerfield Management's 13F filing for Q1 2016, filed 16 May 2016.